Financial Data and Key Metrics Changes - In 2025, the company raised almost $1 billion, ending the year with a cash balance of $1.6 billion, which extends its runway into 2029 [7][31]. - Collaboration revenue for Q4 2025 was $2.9 million, primarily from the partnership with Gilead [29]. - R&D expenses for the quarter were $83.8 million, reflecting a 16% increase from the previous quarter [31]. Business Line Data and Key Metrics Changes - The company launched its first phase IIb study for KT-621 in atopic dermatitis and started a phase IIb study for asthma early in 2026, indicating significant progress in its clinical pipeline [6][8]. - The phase IIb trials for KT-621 are expected to generate data from close to 500 patients next year [23]. Market Data and Key Metrics Changes - The market for type 2 diseases is characterized as very early in its development, with approximately 140 million diagnosed patients in the U.S., five major EU countries, and Japan, but only about 2 million currently receiving advanced systemic therapies [11][15]. - The annual market value for the segment currently treated with advanced systemic therapies is estimated at about $20 billion, with significant room for expansion as many patients remain untreated [14][15]. Company Strategy and Development Direction - The company aims to develop breakthrough immunology medicines, focusing on oral therapies that can provide effective treatment for type 2 diseases without the burdens associated with current injectable biologics [5][10]. - The strategy includes advancing existing collaborations and targeting new development candidates annually, with a focus on expanding the pipeline [9][10]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of KT-621 to significantly increase the number of patients treated effectively, addressing the unmet needs in the type 2 disease market [10][17]. - The company anticipates a busy 2026 with multiple milestones, including data releases from ongoing trials and the initiation of new studies [8][9]. Other Important Information - The company recently appointed Neil Graham as Chief Development Officer, bringing over 30 years of experience in global drug development [9][10]. - The company is focused on ensuring patient adherence in clinical trials, emphasizing the advantages of oral therapies over injectables [78]. Q&A Session Summary Question: What is the vision for the treatment of atopic dermatitis (AD) and how do these therapies fit together? - Management highlighted the need for more therapies in the AD market, which is still early in development, and emphasized the potential for new therapies to benefit both patients and companies [36][37]. Question: What can be learned in the healthy volunteer portion of the IRF5 trial? - Management noted that demonstrating 90% or greater IRF5 knockdown in blood is crucial for de-risking subsequent patient studies, despite the lack of circulating biomarkers [39][40]. Question: Will there be interim analyses for the phase IIb studies? - Management stated that due to the importance of maintaining study integrity, data will be shared only at the end of the studies [48]. Question: How does the company prioritize development for the IRF5 program? - Management indicated that the genetic association with diseases like lupus and Sjögren's, combined with preclinical data, guides their development priorities [50][51]. Question: What are the requirements to start phase III studies for KT-621? - Management clarified that completion of phase II studies and an FDA meeting are necessary before initiating phase III studies [62].

Financial Data and Key Metrics Changes - In 2025, the company raised almost $1 billion, ending the year with a cash balance of $1.6 billion, which extends its runway into 2029 [7][31][32] - Research and Development (R&D) expenses for Q4 2025 were $83.8 million, reflecting a 16% increase from the previous quarter [31] - General and Administrative (G&A) expenses for the quarter were $16.9 million, with an adjusted cash G&A spend of $10 million, reflecting a 1% increase from the previous quarter [31] Business Line Data and Key Metrics Changes - Collaboration revenue in Q4 2025 was $2.9 million, primarily from the partnership with Gilead [29] - The company initiated a Phase 2b study for KT-621 in atopic dermatitis and asthma, with both studies benefiting from positive data shared previously [6][21] Market Data and Key Metrics Changes - The company estimates that there are about 140 million diagnosed type 2 patients in the U.S., five major EU countries, and Japan, with only about 2 million currently treated with advanced systemic therapies [11][14] - The annual market value for the segment currently receiving advanced systemic therapies is approximately $20 billion, with significant unmet needs indicating potential for market expansion [14][15] Company Strategy and Development Direction - The company aims to develop breakthrough immunology medicines, focusing on oral therapies that can provide effective treatment for type 2 diseases without the burdens associated with current therapies [5][10] - The strategy includes advancing existing collaborations and launching new partnerships to enhance its pipeline, with a goal of announcing at least one new program annually [9][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of KT-621 to significantly increase the number of patients treated effectively, addressing the unmet needs in the type 2 disease market [10][17] - The company plans to report data from ongoing trials and continue building awareness of its programs, with a focus on expanding its pipeline and achieving multiple milestones in 2026 [8][9] Other Important Information - The company recently appointed Neil Graham as Chief Development Officer, bringing over 30 years of experience in global drug development [9][10] - The company is focused on advancing its IRF5 degrader program, KT-579, with plans to report first-in-human data in the second half of 2026 [26][27] Q&A Session Summary Question: What is the vision for the treatment of atopic dermatitis (AD) and how do these therapies fit together? - Management highlighted that the AD market is still early, with a significant need for new therapies, and emphasized the importance of bringing new options to market to benefit patients [36][38] Question: What can be learned in the healthy volunteer portion of the IRF5 trial? - Management noted that the primary objectives are safety and demonstrating significant IRF5 knockdown, which is crucial for de-risking subsequent patient studies [39][40] Question: Will there be interim analyses for the Phase 2b studies? - Management indicated that while they would like to gather data along the way, the integrity of the placebo-controlled studies necessitates waiting until the end to unblind and share results [46][48] Question: What informs the priorities for the IRF5 program? - Management stated that the genetic association with diseases like lupus and Sjögren's, combined with preclinical data, guides their development priorities [50][51] Question: What are the gating factors for starting Phase 2 studies outside of asthma and AD? - Management clarified that they plan to use ongoing studies to support late development in other indications and do not intend to start new Phase 2 studies until they are ready for registrational studies [55][56] Question: What is the trigger to start the KT-621 Phase 3 studies? - Management explained that they need to complete Phase 2 studies and have an FDA meeting before starting Phase 3, with plans to initiate multiple studies in parallel if the current paradigm continues [60][63]